Piramal Pharma Stock Screener | Share Price & Fundamental Analysis
PPLPHARMA
Pharmaceuticals
Share Price NSE
₹141.04
▼
-0.50 (-0.35%)
Share Price BSE
₹141.05
▼
-0.45 (-0.32%)
Track Piramal Pharma share price live with TickJournal's free stock screener.
Analyze Piramal Pharma share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Piramal Pharma Market Cap
₹18,899.25 Cr.
PPLPHARMA P/E Ratio (TTM)
-116.06
Piramal Pharma P/B Ratio
2.35
EPS (TTM)
₹0.69
Dividend Yield
0.10%
Debt to Equity
0.60
PPLPHARMA 52 Week High
₹224.46
Piramal Pharma 52 Week Low
₹133.27
Operating Margin
20.00%
Profit Margin
5.48%
PPLPHARMA Revenue (TTM)
₹2,812.00
EBITDA
₹619.00
Net Income
₹154.00
Total Assets
₹15,678.00
Total Equity
₹8,126.00
Piramal Pharma Share Price History - Stock Screener Chart
Screen PPLPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Piramal Pharma Company Profile - Fundamental Screener
Screen Piramal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for PPLPHARMA shares.
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Nandini Piramal
ISIN
INE0DK501011
Website
https://www.piramalpharma.com
Piramal Pharma Balance Sheet Screener
Screen PPLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 15,678 | 15,312 | 14,523 | 12,797 | 10,900 |
| Current Assets | 5,797 | 5,465 | 4,836 | 4,067 | 3,649 |
| Fixed Assets | 8,133 | 7,990 | 7,469 | 6,879 | 6,106 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3,786 | 3,031 | 3,906 | 3,067 | 2,805 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 8,126 | 7,911 | 6,774 | 6,697 | 5,605 |
| Share Capital | 1,324 | 1,323 | 1,193 | 1,186 | 995 |
| Reserves & Surplus | 6,801 | 6,588 | 5,580 | 5,511 | 4,610 |
Piramal Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Piramal Pharma income statement and profit fundamentals.
Analyze PPLPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Piramal Pharma share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,812 | 2,031 | 2,124 | 2,193 | 2,591 | 1,993 | 2,320 | 2,233 | 2,196 | 1,802 | 1,980 | 2,034 | 2,229 | 1,574 | 1,777 |
| Expenses | 2,193 | 1,827 | 1,885 | 1,985 | 2,053 | 1,747 | 1,900 | 1,867 | 1,812 | 1,617 | 1,646 | 1,723 | 1,733 | 1,465 | 1,554 |
| EBITDA | 619 | 204 | 239 | 208 | 538 | 246 | 420 | 367 | 384 | 185 | 334 | 312 | 495 | 109 | 223 |
| Operating Profit % | 20.00% | 6.00% | 8.00% | 7.00% | 20.00% | 10.00% | 15.00% | 15.00% | 16.00% | 8.00% | 14.00% | 12.00% | 19.00% | 1.00% | 10.00% |
| Depreciation | 243 | 197 | 203 | 213 | 196 | 185 | 192 | 197 | 184 | 174 | 185 | 186 | 165 | 162 | 166 |
| Interest | 104 | 86 | 82 | 89 | 114 | 107 | 108 | 103 | 104 | 119 | 110 | 106 | 57 | 62 | 83 |
| Profit Before Tax | 273 | -79 | -46 | -94 | 228 | -45 | 120 | 67 | 95 | -107 | 40 | 19 | 273 | -115 | -26 |
| Tax | 119 | 3 | 53 | 42 | 126 | 44 | 98 | 63 | 45 | -9 | 35 | 9 | 69 | -6 | 11 |
| Net Profit | 154 | -82 | -99 | -136 | 101 | -89 | 23 | 4 | 50 | -99 | 5 | 10 | 204 | -109 | -37 |
| EPS | 1.16 | -0.62 | -0.75 | -1.03 | 0.77 | -0.67 | 0.17 | 0.03 | 0.42 | -0.83 | 0.04 | 0.08 | 1.72 | -0.92 | -0.31 |
Piramal Pharma Cash Flow Screener - Liquidity Fundamentals
Screen PPLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | 892 | 1,005 | 484 | 766 | 598 |
| Investing Activities | -488 | -416 | -1,334 | -1,737 | -4,464 |
| Financing Activities | -441 | -422 | 818 | 794 | 3,977 |
| Net Cash Flow | -37 | 166 | -32 | -177 | 110 |
Piramal Pharma Shareholding Pattern Screener
See Piramal Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Piramal Pharma promoter holding and ownership changes for PPLPHARMA on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 34.95% | 34.86% | 34.86% | 34.86% | 35.02% | 34.95% | 34.95% | 34.95% |
| FII Holding | 31.49% | 30.86% | 30.27% | 29.66% | 30.59% | 31.42% | 31.73% | 31.68% |
| DII Holding | 14.78% | 14.26% | 14.89% | 15.69% | 12.12% | 12.95% | 13.81% | 14.10% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.11% | 14.07% | 14.12% | 14.11% | 15.13% | 13.94% | 13.29% | 13.29% |
| Other Holding | 5.66% | 5.95% | 5.86% | 5.69% | 7.14% | 6.74% | 6.22% | 5.98% |
| Shareholder Count | 432,843 | 458,430 | 462,511 | 453,830 | 297,996 | 306,398 | 359,751 | 418,442 |
Piramal Pharma Share Dividend Screener - Share Yield Analysis
Check Piramal Pharma dividend history with payout and yield data.
View Piramal Pharma dividend details including ex-dates and amounts for PPLPHARMA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.14 | 0.10% |
| 2024-March | ₹0.11 | 0.05% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.56 | 0.84% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Piramal Pharma Stock Index Membership
See which indices include Piramal Pharma stock.
Check PPLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEIPO
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
BSE INDEX SMLSEL
NIFTY 500
NIFTY ALPHA 50
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
Piramal Pharma Market Events Screener - Corporate Actions
Get Piramal Pharma corporate actions including splits, bonuses, and buybacks.
Check Piramal Pharma stock events that may affect PPLPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | -9.31% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | -1.56% |
| 2025-07-30 | 2025-07-30 | Annual General Meeting | NA | 2.83% |
| 2025-07-28 | 2025-07-28 | Quarterly Result Announcement | NA | -6.75% |
| 2025-07-16 | 2025-07-16 | Dividend | ₹ 0.14 /share | 0.61% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -0.02% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | 1.24% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | -2.78% |
| 2024-07-26 | 2024-07-26 | Annual General Meeting | NA | 5.86% |
| 2024-07-12 | 2024-07-12 | Dividend | ₹ 0.11 /share | 2.40% |
| 2023-08-02 | 2023-08-02 | Rights | 5:46 | 1.87% |
Piramal Pharma Competitors Screener - Peer Comparison
Screen PPLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Piramal Pharma Company Announcements - News Screener
Screen PPLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-04 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Completion Of Acquisition Of Kenalog® A Branded Commercial Injectable Product | - |
| 2026-03-20 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Ratings | - |
| 2026-03-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-24 | Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-14 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revocation Of Closure Direction For CompanyS Dahej Site | - |
| 2026-02-14 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA Inspection | - |
| 2026-02-11 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-04 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-01-29 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-01-29 | Results - Financial Results For The Quarter Ended December 31 2025 | - |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-01-28 | Announcement Under Regulation 30 (LODR)- Acquisition Of Kenalog® A Branded Commercial Injectable Product | - |
| 2026-01-28 | Board Meeting Outcome for Outcome Of Board Meeting Dated January 28 2026 | - |